TTrialPathMatch Me to Trials
← Back to trials
RecruitingAsthmaAsthma PatientsAsthma Bronchiale

Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.

Sponsor: Chiesi Slovenija, d.o.o.

You may qualify if…

  • ✓ Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
  • ✓ Patients ≥ 18 years of age in ambulatory care
  • ✓ Uncontrolled asthma according to the physician's clinical assessment despite the use of:
  • ✓ 1. LABA and high dose ICS or
  • ✓ 2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.
  • ✓ Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC :
  • ✓ 1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months
  • ✓ 2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20)

You may not qualify if…

  • ✕ Participation in any clinical trial within 30 days prior to enrolment
  • ✕ Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment
  • ✕ Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment.
  • ✕ Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids
  • ✕ Use of continuous oxygen therapy
  • ✕ Any malignant disease in the last 5 years
  • ✕ Tuberculosis (active or anamnestic)
  • ✕ Actual or previous use of biologics for asthma treatment in the past 12 months

Source: ClinicalTrials.gov · NCT07489911 · last updated 2026-03-24